Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight ...

MAMII brings together industry leaders, technology innovators, and maritime stakeholders to advance technologies for measuring and mitigating methane emissions in the maritime sector ...